View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 3, 2017

LabCorp completes acquisition of Chiltern for $1.2bn

US-based global life sciences company LabCorp has completed the acquisition of Chiltern, a specialist contract research organisation (CRO), for approximately $1.2bn.

By Lopamudra Roy

US-based global life sciences company LabCorp has completed the acquisition of Chiltern, a specialist contract research organisation (CRO), for approximately $1.2bn.

In July, LabCorp confirmed its intention to acquire Chiltern pursuant to a definitive agreement with the shareholders of the CRO.

With the acquisition, Chiltern will now become a part of LabCorp’s Covance Drug Development business.

The conclusion of the deal has created a market-leading CRO, with more than 20,000 employees worldwide, thereby increasing Covance’s offerings as a partner serving the high-growth emerging and mid-market biopharma segments.

LabCorp chairman and chief executive officer David P. King said: “The addition of Chiltern advances a key element of LabCorp’s strategy – to bring innovative medicines to patients faster, which ultimately will improve patient outcomes.

"The addition of Chiltern advances a key element of LabCorp’s strategy – to bring innovative medicines to patients faster, which ultimately will improve patient outcomes."

“We are delighted to welcome our Chiltern colleagues and look forward to driving growth and innovation as we offer enhanced solutions to our biopharmaceutical customers.”

With the acquisition, the Covance executive team will include Chiltern officials and will comprise existing members from both the companies.

Covance CEO John Ratliff said: “The powerful combination of Covance and Chiltern enables us to provide enhanced customer offerings, including expanded functional service provider solutions and leading oncology expertise.”

This year, Chiltern has estimated its revenue and adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) to reach approximately $550m and $95m, respectively.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU